2024-10-17T09:51:47-05:00 2023-12-31 873231666 PKF O'CONNOR DAVIES ADVISORY LLC 500 MAMARONECK AVENUE SUITE 301 HARRISON NY 105281633 990 2023-01-01 450553664 HEALTHIX INC HEAL 8776954749 462 SEVENTH AVENUE 8TH FLOOR NEW YORK NY 10018 JOHN GUASTELLA SVP & CFO 8776954749 2024-10-17 1 1 MELISSA MODELSON P01603524 9143818900 2024-10-16 2023 2024-10-15 13:58:12Z TODD M ROGOW 462 SEVENTH AVENUE 8TH FLOOR NEW YORK NY 10018 24973489 0 X WWW.HEALTHIX.ORG X 2007 NY THE MISSION OF THE COMPANY IS TO CREATE AN ACHIEVABLE, SUSTAINABLE AND REPLICABLE MODEL FOR INTEGRATING CLINICAL INFORMATION ACROSS MULTIPLE HEALTH CARE ORGANIZATIONS WHICH SUPPORTS NEW YORK STATE AND FEDERAL STRATEGIC HEALTH INFORMATION TECHNOLOGY (HIT) PLANS TO (A) IMPROVE ACCESS TO PATIENT DATA AT THE POINT OF CARE; (B) IMPROVE HEALTH CARE QUALITY; AND (C) REDUCE INAPPROPRIATE UTILIZATION AND COST. 19 19 93 26 0 0 19859197 20003787 1027148 4397628 3459 572074 41000 0 20930804 24973489 0 0 0 0 12514927 14277493 0 0 0 8200319 10202871 20715246 24480364 215558 493125 25869695 26541737 5397765 5576682 20471930 20965055 X THE MISSION OF HEALTHIX INC. IS TO CREATE AN ACHIEVABLE, SUSTAINABLE AND REPLICABLE MODEL FOR INTEGRATING CLINICAL INFORMATION ACROSS MULTIPLE HEALTH CARE ORGANIZATIONS WHICH SUPPORTS NEW YORK STATE AND FEDERAL STRATEGIC HEALTH INFORMATION TECHNOLOGY (HIT) PLANS TO (A) IMPROVE ACCESS TO PATIENT DATA AT THE POINT OF CARE; (B) IMPROVE HEALTH CARE QUALITY; AND (C) REDUCE INAPPROPRIATE UTILIZATION AND COST. 0 0 21242359 0 4397628 SHIN-NY GRANT/HCRA/MEDICAID PROGRAMPROGRAM DESCRIPTIONHEALTHIX WORKS WITH OUR PARTICIPANTS TO INTEGRATE THEM INTO THE HIE AND TO WORK WITH THEM TO DESIGN AND DEVELOP PRODUCTS AND SERVICES THAT HELP THEM TO IMPROVE CARE THROUGH BETTER CARE COORDINATION. IN 2023 WE USED THE FUNDING FROM SHIN-NY/HCRA/MEDICAID TO SUPPORT CUSTOMER ENGAGEMENT, COMPLIANCE, RELATIONSHIP MANAGEMENT, PROJECT MANAGEMENT, OPERATIONS, DEVELOPMENT, DATA QUALITY IMPROVEMENT, ENGINEERING, QUALITY ASSURANCE AND SUPPORT. OUR CUSTOMER ENGAGEMENT TEAM RECRUITED NEW PARTICIPANTS, ENSURED COMPLIANCE WITH STATE PRIVACY & SECURITY POLICIES AND PREPARED STATEMENTS OF WORK TO HAND OFF TO THE PROJECT MANAGEMENT, CUSTOMER EXPERIENCE AND DEVELOPMENT & ENGINEERING TEAMS.CUSTOMER ENGAGEMENT TEAM WAS COMPRISED OF TWO CUSTOMER ENGAGEMENT MANAGERS REPORTING INTO THE VICE PRESIDENT OF CUSTOMER EXPERIENCE. THE COMPLIANCE DEPARTMENT IS COMPRISED OF AN ASSISTANT VICE PRESIDENT OF COMPLIANCE AND PRIVACY OFFICER AND FIVE COMPLIANCE STAFF. THE PROJECT MANAGEMENT DEPARTMENT IS COMPRISED OF A VICE PRESIDENT, FIVE PROJECT MANAGERS, A PROJECT MANAGEMENT TEAM LEAD, A QUALITY ASSURANCE LEAD, TWO QUALITY ASSURANCE ENGINEERS, A MANAGER OF OPERATIONS WITH TWO ANALYSTS AND A TRAINING SPECIALIST. THE CUSTOMER EXPERIENCE TEAM IS COMPRISED OF A VICE PRESIDENT, A DIRECTOR OF RELATIONSHIP MANAGEMENT WITH EIGHT RELATIONSHIP MANAGERS, A COMMUNICATIONS MANAGER, AN ASSISTANT VICE PRESIDENT OF CUSTOMER SUPPORT WITH SEVEN CUSTOMER SUPPORT STAFF. THE DEVELOPMENT OPERATIONS TEAM IS LED BY A SENIOR DIRECTOR AND COMPRISED OF A DIRECTOR OF DATA STRATEGY AND EIGHT DATA ANALYSTS, A DIRECTOR OF DEVELOPMENT WITH FIVE INTEGRATION ENGINEERS AND A SYSTEMS ENGINEERING TEAM COMPRISED OF EIGHT NETWORK ENGINEERS. THE INFORMATION SECURITY GROUP REPORTS INTO THE CIO AND IS COMPRISED OF A CHIEF INFORMATION SECURITY OFFICER AND TWO INFORMATION SECURITY ANALYSTS. IN ADDITION, THE SHIN-NY GRANT/HCRA/MEDICAID PROGRAM FUNDING SUPPORTED OFFICE SPACE AND DATA CENTER OPERATIONS.ACCOMPLISHMENTSIN 2023 HEALTHIX COMPLETED 271 PROJECTS INCLUDING CUSTOMER PROJECTS, INTERNAL PROJECTS, VENDOR DEVELOPMENT PROJECTS, PRODUCT DEVELOPMENT PROJECTS, GRANTS PROJECTS AND PUBLIC HEALTH PROJECTS. THE CUSTOMER PROJECTS INCLUDED CONNECTING NEW PARTICIPANTS TO HEALTHIX AND PROVIDING THEM WITH STANDARD AND CUSTOM SERVICES. AT THE BEGINNING OF 2023, HEALTHIX LAUNCHED A NEW SERVICE TO SUPPORT PROVIDERS IN POPULATION HEALTH AND VALUE-BASED CARE. THE NEW SERVICE IS DESIGNED TO HELP PROVIDERS IDENTIFY AND FOLLOW UP WITH HIGH-RISK PATIENTS AND MEET QUALITY MEASURES AND ACHIEVE HIGHER INCENTIVE PAYMENTS. HEALTHIX HAS INVESTED IN THE DEVELOPMENT AND SUBSIDIZED THE LICENSE FEES IN ORDER TO ENHANCE ADOPTION. AS THE PRODUCT MATURES AND IS ABLE TO DEMONSTRATE VALUE, CUSTOMERS WILL BE ASKED TO PAY MARKET RATES FOR THE SERVICE AND PROVIDE A NEW REVENUE STREAM FOR HEALTHIX.DURING THE YEAR ENDED DECEMBER 31, 2023, THE COMPANY RECORDED $19,079,214 IN REVENUE IN CONNECTION WITH THIS PROGRAM.NYC DOHMHIN 2023 HEALTHIX CONTINUED A TWO-YEAR CONTRACT WITH THE NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE (DOHMH) TO DEVELOP NEW FUNCTIONALITY AND INFRASTRUCTURE IMPROVEMENTS TO ENHANCE THE DEPARTMENT'S ABILITY TO PERFORM DISEASE SURVEILLANCE AND EPIDEMIOLOGY. THE YEAR 2 CONTRACT WAS EXECUTED IN JUNE OF 2023.HYPERTENSION PROGRAM HRI HEALTH RESEARCHTHE HTN PROJECT CONSISTS OF PARTNERING WITH NYS DEPARTMENT OF HEALTH TO ANALYZE HEALTHIX'S 2021 DATASET TO GET A CLOSER LOOK INTO THE CHRONIC DISEASE OF HYPERTENSION. THE PROJECT PROVIDED AN IN-DEPTH OPPORTUNITY FOR HEALTHIX TO CLINICALLY EVALUATE AND UNDERSTAND THE ISSUES PERTAINING TO HYPERTENSION WITHIN OUR PATIENT POPULATION. WE REVIEWED THE FOLLOWING CRITERIA'S, HYPERTENSION PREVALENCE, CONTROLLED AND UNDIAGNOSED HYPERTENSION MEASURES. WE STRATIFIED THE DATA BY AGE, GENDER, ZIP CODE, COUNTY, RACE AND ETHNICITY IN DETAIL. WE ANALYZED PRIMARY VS SECONDARY HYPERTENSION MEASURES FOR HEALTHIX'S CATCHMENT AREA WITHIN NYC AND LONG ISLAND FOR PATIENTS 18-85 OF AGE. WE ALSO ANALYZED PATIENTS OUTSIDE OF HEALTHIX CATCHMENT AREA AND THE NON-HYPERTENSION PATIENTS WITHIN THE SAME STUDY YEAR. HEALTHIX REVIEWED LOCAL AND STANDARD DIAGNOSIS DATA AND STANDARDIZED PATIENTS THAT ARE SOLELY HYPERTENSIVE VS PATIENTS WITH ANOTHER UNDERLYING DISEASE-CAUSING HYPERTENSION. OUR FINDINGS WITHIN OUR DATASET INCLUDE THE FOLLOWING:- MAJORITY LOWEST ZIPS WERE IN THE BRONX- MAJORITY HIGHEST ZIPS FOR HTN PATIENTS WITHIN OUR DATASET ARE IN QUEENS AND BROOKLYN- 10.2MILLION DISTINCT INDIVIDUALS ARE NON-HYPERTENSION PATIENTS WITHIN 2021 - 1.4MILLION DISTINCT INDIVIDUALS ARE HYPERTENSION PATIENTS WITHIN 2021- MAJORITY OF PATIENTS WITH HTN ARE ADULTS AGES 50+- HTN PATIENTS AGES 18-85 PREVALENCE RATE = 93.4% - HTN CONTROLLED PATIENTS AGES 18-85 CONTROL RATE = 61.1%, AROUND 2/3 OF THE POPULATION IS TAKING CONTROL MEASURETHE PROJECT OUTCOME WAS A SUCCESS AND HEALTHIX WILL BE LAUNCHING A LIVE HYPERTENSION CLINICAL DASHBOARD BY END OF 2024 TO TRACK PATIENTS' HEALTH OUTCOME WITHIN THIS TROUBLING DISEASE. PUBLIC HEALTH DATA LAKEGOALTHE GOAL OF THIS PROJECT WAS TO SEND DATA TO A PUBLIC HEALTH DATA LAKE FOR USE BY THE NYS DOHDESCRIPTIONAS PART OF THE SHIN-NY, HEALTHIX WAS RESPONSIBLE FOR SUBMISSION OF ADT (PATIENT ADMITS AND DISCHARGES) AND ORU(LAB AND RADIOLOGY RESULTS) FROM OUR PARTICIPANTS INTO THE SHIN-NY DATA LAKE COVID DATA FOR PATIENTS WITHIN OUR CATCHMENT AREA. THIS WAS ACCOMPLISHED THROUGH CONVERTING THE ADT AND ORU MESSAGES TO FHIR AND AN AUTOMATED PUSH OF THE FHIR MESSAGES TO THE DATA LAKE.DURING THE YEAR ENDED DECEMBER 31, 2023, THE COMPANY RECORDED $285,000 IN REVENUE IN CONNECTION WITH THIS PROGRAM.CIVITAS/GRAVITY PROJECTGOALTO STANDARDIZE THE FORMAT AND DELIVERY OF HEALTH-RELATED SOCIAL NEEDS (HRSN) FOR DELIVERY INTO THE SHIN-NY DATA LAKE.DESCRIPTIONHEALTHIX WAS A PARTICIPANT IN THE CONVERSATIONS AND DESIGN DECISIONS TO ALIGN ALL THE QUALIFIED ENTITIES (PARTICIPANTS IN THE SHIN-NY) ON THE FORMAT AND DATA TO BE INCLUDED IN THE SUBMISSION OF HRSN DATA INTO THE SHIN-NY DATA LAKE IN ANTICIPATION OF THE 1115 WAIVER.DURING THE YEAR ENDED DECEMBER 31, 2023, THE COMPANY RECORDED $50,000 IN REVENUE IN CONNECTION WITH THIS PROGRAM.COVID REGISTRYGOALTHE GOAL OF THIS PROJECT WAS TO AGGREGATE COVID TEST RESULTS AT THE STATEWIDE LEVEL TO PROVIDE A COMPREHENSIVE VIEW OF ALL COVID PATIENTS THROUGHOUT NY STATE.DESCRIPTIONAS PART OF THE SHIN-NY, HEALTHIX WAS RESPONSIBLE FOR SUBMISSION OF CONTINUITY OF CARE DOCUMENTS (CCD/CCDAS) TO THE SHIN-NY COVID DATA REPOSITORY FOR PATIENTS WITHIN OUR CATCHMENT AREA. THIS WAS ACCOMPLISHED THROUGH AN AUTOMATED PUSH OF A CCD/CCDA FOR PATIENT WHO HAD A POSITIVE COVID TEST RESULT.DURING THE YEAR ENDED DECEMBER 31, 2023, THE COMPANY RECORDED $53,073 IN REVENUE IN CONNECTION WITH THIS PROGRAM.AMBULATORY SURGERY CENTERS I&IGOALTO CONNECT AMBULATORY SURGERY CENTERS TO HEALTHIX TO CAPTURE PROCEDURES FOR OUTPATIENT SURGERIES.DESCRIPTIONHEALTHIX ENGAGED 3 MULTI-SITE AMBULATORY SURGERY CENTERS TO INTEGRATE INTO THE SHIN-NY AND PROVIDE INFORMATION ON THE OUTPATIENT PROCEDURES THAT ARE PERFORMED WITHIN THEM.DURING THE YEAR ENDED DECEMBER 31, 2023, THE COMPANY RECORDED $64,000 IN REVENUE IN CONNECTION WITH THIS PROGRAM.CLINITHINK ASTRA ZENECA GOALPROVIDE CONCISE DE-IDENTIFIED DATA ON A SPECIFIED GROUP OF PATIENTS TO ASCERTAIN IF THERE WAS ENOUGH EVIDENCE TO PROMOTE A CLINICAL TRIAL.DESCRIPTIONPROVIDE STRUCTURED DATA AND UNSTRUCTURED DATA TO CLINITHINK INTO THEIR APPLICATION THAT RESIDES IN OUR DATA CENTER. WORK WITH THE CLINITHINK STAFF TO DETERMINE IF THERE IS ENOUGH EVIDENCE TO ADVANCE THE IDEA OF A CLINICAL TRIAL.DURING THE YEAR ENDED DECEMBER 31, 2023, THE COMPANY RECORDED $32,000 IN REVENUE IN CONNECTION WITH THIS PROGRAM. 21242359 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 X 14 0 93 1 0 0 0 0 0 0 0 0 0 0 0 0 X 19 19 0 0 1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY X X JOHN GUASTELLA 8776954749 462 SEVENTH AVENUE 8TH FLOOR NEW YORK NY 10018 DAVID COHEN MD CHAIR 4.00 X X 0 0 0 GERALD J KELLY DO VICE CHAIR 1.00 X X 0 0 0 ROBERT CHALONER VICE CHAIR THRU JULY 2023 1.00 X X 0 0 0 CHARLES KING TREASURER/SECRETARY 1.00 X X 0 0 0 THOMAS EARLY TREASURER/SECRETARY THRU DEC 2023 1.00 X X 0 0 0 LORI ANDRADE DIRECTOR 1.00 X 0 0 0 MICHAEL BOUTON MD DIRECTOR 1.00 X 0 0 0 TAVORA AL BUCHMAN PHD DIRECTOR 1.00 X 0 0 0 PAUL CASALE MD DIRECTOR 1.00 X 0 0 0 GABRIEL M COHEN MD DIRECTOR 1.00 X 0 0 0 LOUISE COHEN DIRECTOR THRU JUN 2023 1.00 X 0 0 0 K TORIAN EASTERLING MD DIRECTOR 1.00 X 0 0 0 ARTHUR GIANELLI DIRECTOR THRU DEC 2023 1.00 X 0 0 0 MICHAEL GUARINO DIRECTOR THRU DEC 2023 1.00 X 0 0 0 DAVID ALAN HORWITZ MD DIRECTOR 1.00 X 0 0 0 IRENE KOCH ESQ DIRECTOR 1.00 X 0 0 0 DAVID LEVENTHAL DIRECTOR 1.00 X 0 0 0 ALEXANDER IZAGUIRRE PHD DIRECTOR THRU FEB 2023 1.00 X 0 0 0 LARRY MCREYNOLDS DIRECTOR 1.00 X 0 0 0 MARC D PARADIS DIRECTOR 1.00 X 0 0 0 DONNA REY EDD DIRECTOR 1.00 X 0 0 0 DAVID SCHIMEL DIRECTOR THRU DEC 2023 1.00 X 0 0 0 FRED S SGANGA DIRECTOR 1.00 X 0 0 0 MATTHEW SIEGLER DIRECTOR 1.00 X 0 0 0 GRETCHEN VAN WYE PHD DIRECTOR 1.00 X 0 0 0 ANUP VIDYARTHY DIRECTOR 1.00 X 0 0 0 TODD M ROGOW PRESIDENT & CEO 40.00 X 503142 0 187225 JOHN GUASTELLA SVP & CFO 40.00 X 327195 0 111044 THOMAS MOORE SVP STRATEGY & PARTNERSHIPS 40.00 X 326169 0 95340 VIVIENNE DESTEFANO SVP CORPORATE AFFAIRS 40.00 X 310778 0 84581 JOHN CHOW CISO 40.00 X 214771 0 72322 NICHOLAS VANDUYNE SVP & CIO 40.00 X 290312 0 104925 MAGDALENA MANDZIELEWSKA AVP, COMPLIANCE & PRIVACY OFFICER 40.00 X 213634 0 49597 MAUREEN O'CONNOR VP CUSTOMER EXPERIENCE & MARKETING 40.00 X 226720 0 62547 KIMBERLY FRANCOIS VP PROJECT MGMT OPERATIONS 40.00 X 235730 0 27846 STEPHANIE SCOTT AVP, HUMAN RESOURCES 40.00 X 205842 0 29463 GERI ALMER CONTROLLER & SR. DIRECTOR FINANCE 40.00 X 204822 0 51570 SUE-ANN VILLANO AVP, SUPPORT SERVICES 40.00 X 201455 0 66965 SHEETAL KAIRAWALA LEAD INTEGRATION ENGINEER 40.00 X 185079 0 88817 HAROLD DEL PINO DIR. BUSINESS REL. MGMT. 40.00 X 174727 0 49401 STEVEN GIANG INTEGRATION ENGINEER 40.00 X 170969 0 38883 3791345 0 1120526 47 0 1 0 J2 INTERACTIVE LLC 2 THIRTEENTH STREET CHARLESTOWN MA 02129 IT CONSULTING/STAFF AUGMENTATION 1587625 IIS TECHNOLOGY 137 COMMERCIAL STREET SUITE 100 PLAINVIEW NY 11803 IT CONSULTING 456556 MEDITOLOGY SERVICES 5256 PEACHTREE ROAD SUITE 190 ATLANTA GA 30341 CONSULTING SERVICES/STAFF AUGMENTATION 360441 CASTLEMARK CONSULTING 2406 OAKLAND DRIVE BONHAM TX 75418 DATA QUALITY CONSULTING 337185 EPLUS TECHNOLOGY INC PO BOX 404398 ATLANTA GA 30384 IT CONSULTING 220981 9 20003787 20003787 CONTRACT REVENUE 518210 4347081 4347081 CONFERENCE REVENUE 518210 50547 50547 4397628 571324 571324 750 0 750 750 750 24973489 4397628 0 572074 3423057 2533481 889576 176597 176597 8177438 7501856 675582 384750 358181 26569 1083563 983353 100210 1032088 906275 125813 156581 137494 19087 56609 49708 6901 317321 283211 34110 261991 230054 31937 216764 185844 30920 7389308 6488551 900757 434256 381320 52936 157451 138258 19193 89819 78870 10949 724014 635755 88259 397957 349446 48511 MOVING EXPENSES 800 702 98 24480364 21242359 3238005 0 348527 1966281 17900261 12282946 2785164 7165100 826621 1105829 1251627 1820073 4068290 2606932 1753342 1461358 1004153 740150 25869695 26541737 3686778 4610299 774582 396184 936405 570199 5397765 5576682 X 20471930 20965055 20471930 20965055 25869695 26541737 493125 0 X X 0 1 X 1 1 1 X 17909110 27777561 22194016 19859197 20003787 107743671 681274 1167985 1353589 1027148 4397628 8627624 18590384 28945546 23547605 20886345 24401415 116371295 0 236700 1387868 1624568 236700 1387868 1624568 114746727 33820 16792 11574 3169 571324 636679 33820 16792 11574 3169 571324 636679 41000 41000 18624204 28962338 23559179 20930514 24972739 117048974 0.98030 0.99360 0.00540 0.00060 X SCHEDULE A, PART III, LINE 12, EXPLANATION OF OTHER INCOME: RECOVERY OF BAD DEBT - 2022 AMOUNT: $ 41,000. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 59411 7808 51603 3068293 1771450 1296843 940586 827674 112912 1461358 OPERATING LEASE LIABILITIES 570199 570199 X 24830192 0 24830192 143297 143297 24973489 24337067 0 24337067 143297 143297 24480364 PART X, LINE 2: THE COMPANY RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS THAT ARE MORE LIKELY THAN NOT TO BE SUSTAINED. MANAGEMENT HAS DETERMINED THAT THE COMPANY HAS NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION OR DISCLOSURE. THE COMPANY IS NO LONGER SUBJECT TO EXAMINATIONS BY THE APPLICABLE TAXING JURISDICTIONS FOR PERIODS PRIOR TO DECEMBER 31, 2020. PART XI, LINE 4B - OTHER ADJUSTMENTS: GAIN ON SALE OF ASSETS REPORTED ON PART VIII, LINE 7 750. CONFERENCE INCOME REPORTED ON PART VIII, LINE 1 AND LINE 2 142,547. PART XII, LINE 4B - OTHER ADJUSTMENTS: GAIN ON SALE OF ASSETS REPORTED ON PART VIII, LINE 7 750. CONFERENCE INCOME REPORTED ON PART VIII, LINE 1 AND LINE 2 142,547. X X X X 0 0 0 0 0 0 0 1 0 TODD M ROGOW PRESIDENT & CEO 449278 0 53105 0 759 0 145300 0 41925 0 690367 0 50776 0 JOHN GUASTELLA SVP & CFO 293009 0 32205 0 1981 0 68449 0 42595 0 438239 0 27191 0 THOMAS MOORE SVP STRATEGY & PARTNERSHIPS 292682 0 30397 0 3090 0 71500 0 23840 0 421509 0 28715 0 VIVIENNE DESTEFANO SVP CORPORATE AFFAIRS 277947 0 30850 0 1981 0 64159 0 20422 0 395359 0 27200 0 NICHOLAS VANDUYNE SVP & CIO 288399 0 0 0 1913 0 70284 0 34641 0 395237 0 0 0 MAUREEN O'CONNOR VP CUSTOMER EXPERIENCE & MARKETING 202767 0 23148 0 805 0 39680 0 22867 0 289267 0 19400 0 JOHN CHOW CISO 191785 0 22220 0 766 0 31052 0 41270 0 287093 0 19162 0 SHEETAL KAIRAWALA LEAD INTEGRATION ENGINEER 165949 0 18896 0 234 0 28094 0 60723 0 273896 0 0 0 SUE-ANN VILLANO AVP, SUPPORT SERVICES 180200 0 20563 0 692 0 28290 0 38675 0 268420 0 17247 0 KIMBERLY FRANCOIS VP PROJECT MGMT OPERATIONS 212278 0 22208 0 1244 0 27330 0 516 0 263576 0 18584 0 MAGDALENA MANDZIELEWSKA AVP, COMPLIANCE & PRIVACY OFFICER 191155 0 21735 0 744 0 30074 0 19523 0 263231 0 18618 0 GERI ALMER CONTROLLER & SR. DIRECTOR FINANCE 182006 0 21735 0 1081 0 26310 0 25260 0 256392 0 17959 0 STEPHANIE SCOTT AVP, HUMAN RESOURCES 185032 0 20563 0 247 0 25851 0 3612 0 235305 0 16875 0 HAROLD DEL PINO DIR. BUSINESS REL. MGMT. 157149 0 17270 0 308 0 25160 0 24241 0 224128 0 0 0 STEVEN GIANG INTEGRATION ENGINEER 161435 0 9425 0 109 0 24109 0 14774 0 209852 0 0 0 PART I, LINE 7 AN EMPLOYEE MAY RECEIVE AN ANNUAL BONUS EQUAL TO AS MUCH AS 12% OF HIS/HER BASE SALARY (EXCEPT FOR THE CEO, WHOSE ANNUAL BONUS IS SET BY HIS EMPLOYMENT AGREEMENT). THE BONUS WILL BE DETERMINED BASED UPON PERFORMANCE OBJECTIVES OUTLINED BY THE EMPLOYEE'S MANAGER AND DISCUSSED WITH THE EMPLOYEE, IN MOST CIRCUMSTANCES, EARLY IN THE FIRST QUARTER OF THE COMPENSATION YEAR. FOR NEW EMPLOYEES, WHOSE FIRST ANNUAL BONUS IS PRORATED FROM THEIR DATE OF HIRE TO THE END OF THE YEAR, THEIR PERFORMANCE OBJECTIVES ARE DISCUSSED WITH THEM SHORTLY AFTER THEY ARE HIRED. ONCE THE COMPANY'S FISCAL YEAR HAS ENDED, A PERFORMANCE EVALUATION IS PREPARED TO SEE IF THE EMPLOYEE HAS MET THE CRITERIA FOR INCENTIVE PAY FOR THE PERFORMANCE OBJECTIVES OUTLINED, AND THE MANAGER DETERMINES HOW THE EMPLOYEE HAS PERFORMED. AN OVERALL RATING IS ASSIGNED TO THE PERFORMANCE. THIS OVERALL RATING IS THE DETERMINING FACTOR FOR THE PERCENTAGE BONUS WHICH THE EMPLOYEE HAS EARNED FOR THE PREVIOUS FISCAL YEAR. A SCHEDULE IS DISTRIBUTED TO ALL EMPLOYEES WHICH SHOWS THE PERCENTAGE BONUS AN EMPLOYEE CAN EARN BASED UPON HOW THEIR PERFORMANCE IS RATED. THIS SCHEDULE ALSO BRIEFLY SUMMARIZES THE COMPANY'S INCENTIVE COMPENSATION PROGRAM. THIS IS DISTRIBUTED TO EMPLOYEES IN THE COMPENSATION YEAR SO THAT EACH EMPLOYEE AND THEIR MANAGER ARE AWARE OF WHAT CAN BE EARNED. PAYMENT OF ANY INCENTIVE COMPENSATION IS WHOLLY DEPENDENT UPON THE COMPANY MEETING ITS OPERATING INCOME TARGET, AS IS ESTABLISHED AT THE BEGINNING OF EACH FISCAL YEAR AND APPROVED BY THE BOARD OF DIRECTORS. ONCE THE COMPANY'S BOOKS ARE CLOSED IN THE SUBSEQUENT PERIOD, THE COMPANY THEN COMPARES ITS ACTUAL OPERATING INCOME TO ITS TARGETED OPERATING INCOME. ASSUMING THE OPERATING INCOME TARGET IS MET OR EXCEEDED, MANAGEMENT THEN INFORMS THE HEALTHIX FINANCE COMMITTEE OF THIS. PROPOSED BONUSES ARE THEN SUBMITTED TO THE CEO (OR PREPARED BY HIM FOR HIS DIRECT REPORTS). AS LONG AS THE BONUSES ARE WITHIN THE AMOUNTS BUDGETED BY THE COMPANY, THE EXECUTIVE COMMITTEE HAS GIVEN THE CEO THE AUTHORITY TO APPROVE THE BONUS PAYMENTS. THE BONUS PAYMENTS TO BE PAID OCCURS IN THE FIRST QUARTER OF THE YEAR FOLLOWING THE YEAR IN WHICH THEY WERE EARNED (THE COMPENSATION YEAR). INCENTIVE COMPENSATION EARNED IN 2022 AND PAID/TAXABLE IN 2023 IS REPORTED ON SCHEDULE J, PART II, COLUMN B (II). SEE PART V SEE PART V 75827 SEE PART V 0 SEE PART V SEE PART V 100770 SEE PART V 0 FORM 990, SCHEDULE L, PART IV, LINE 1: NAME OF INTERESTED PERSON: JUSTIN CHOWRELATIONSHIP BETWEEN THE INTERESTED PERSON AND ORGANIZATION: FAMILY MEMBER OF THE CISODESCRIPTION OF TRANSACTION: JUSTIN CHOW IS AN EMPLOYEE OF HEALTHIX FORM 990, SCHEDULE L, PART IV, LINE 2: NAME OF INTERESTED PERSON: DARREL LACEYRELATIONSHIP BETWEEN THE INTERESTED PERSON AND ORGANIZATION: FAMILY MEMBER OF THE AVP, HUMAN RESOURCESDESCRIPTION OF TRANSACTION: DARREL LACEY IS AN EMPLOYEE OF HEALTHIX NYC DOHMH PUBLIC HEALTH INTEGRATION GOAL PROVIDE ACCESS TO THE HEALTHIX DATA FOR USE IN PUBLIC HEALTH SURVEILLANCE. DESCRIPTION IN PARTNERSHIP WITH NYC DOHM, HEALTHIX IS ESTABLISHING INTERFACES THAT ALLOW US TO PUSH DATA TO NYC DOHMH IN A FHIR FORMAT IF A DIAGNOSIS MEETS THE CRITERIA PROVIDED BY NYC DOHMH. ADDITIONALLY, HEALTHIX WILL ALLOW NYC DOHMH TO QUERY FOR DATA FOR THE PURPOSES OF PUBLIC HEALTH. DURING THE YEAR ENDED DECEMBER 31, 2023, THE COMPANY RECORDED $1,218,116 IN REVENUE IN CONNECTION WITH THIS PROGRAM. SMART ON FHIR(HIXNY) GOAL TO PROVIDE CLINICIANS ACCESS TO HIE DATA THROUGH AN APPLICATION INTEGRATED IN THE EMR SYSTEM. DESCRIPTION IN PARTNERSHIP WITH HIXNY (ANOTHER QE IN THE SHIN-NY NETWORK) DEPLOY AN APPLICATION WIDGET THAT INCORPORATES INTO THE EMR SYSTEM OF HOSPITALS AND PROVIDERS. USING THE WIDGET RETRIEVE DATA FROM HEALTHIX ON THE PATIENT WHOSE CHART THE CLINICIAN CURRENTLY HAS OPEN WITHOUT DISRUPTING THEIR WORKFLOW. DURING THE YEAR ENDED DECEMBER 31, 2023, THE COMPANY RECORDED $50,000 IN REVENUE IN CONNECTION WITH THIS PROGRAM. FORM 990, PART I, QUESTION 5, AND PART V, QUESTION 2A: THE ORGANIZATION CONTRACTED WITH A PROFESSIONAL EMPLOYER ORGANIZATION (PEO) FOR SERVICES, INCLUDING BUT NOT LIMITED TO, PAYROLL, TIMEKEEPING, EMPLOYEE BENEFITS, HR ADMINISTRATION AND WORKFORCE REGULATORY COMPLIANCE NEEDS. AS THE EMPLOYER OF RECORD FOR TAX PURPOSES, FORMS W-2 AND W-3 ARE ISSUED BY THE PEO AND FILED UNDER THE PEO'S FEDERAL EIN. IN THIS CO-EMPLOYMENT ARRANGEMENT, THE ORGANIZATION IS THE COMMON LAW EMPLOYER AND, ACCORDINGLY, COMPENSATION IS REPORTED ON FORM 990, PART VII, SECTION A AND PART IX, LINES 5-10. FORM 990, PART VI, SECTION A, LINE 4 THE BY-LAWS WERE AMENDED BY THE BOARD IN 2023 TO REMOVE THE MEMBER CLASS. THE RESPONSIBILITY OF MEETING AS MEMBERS ARE REMOVED AND PLACES ALL THE FORMER MEMBER CLASS RIGHTS AND OBLIGATIONS ON THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11B AFTER THE FORM IS PREPARED BY OUTSIDE ACCOUNTANTS, IT WILL FIRST BE REVIEWED BY THE SVP/CFO. IF THERE ARE ANY SUGGESTED CHANGES OR MODIFICATIONS, HE WILL COMMUNICATE DIRECTLY WITH THE OUTSIDE ACCOUNTANTS. ONCE THE SVP/CFO IS SATISFIED WITH THE 990, HE WILL PASS IT ON TO THE CEO FOR HIS REVIEW. ONCE THE CEO IS SATISFIED WITH THE 990, THE NEXT STEP IS TO PASS IT ON TO THE CHAIRMAN OF THE FINANCE COMMITTEE, WHO IS A MEMBER OF THE EXECUTIVE COMMITTEE AND THE BOARD OF DIRECTORS, FOR HIS REVIEW. ONCE THIS INDIVIDUAL IS SATISFIED WITH THE 990, IT WILL BE PASSED ON TO THE FULL EXECUTIVE COMMITTEE. THIS COMMITTEE IS A SUBSET OF THE FULL HEALTHIX, INC. BOARD AND IS CHARGED WITH MAKING MANY KEY DECISIONS AFFECTING THE COMPANY. IT IS THIS GROUP OF INDIVIDUALS THAT WILL AUTHORIZE THE FILING OF THE 990. ONCE THE EXECUTIVE COMMITTEE IS SATISFIED WITH THE 990 AND HAS AUTHORIZED ITS FILING, THE SVP/CFO WILL PROVIDE AN ELECTRONIC COPY TO THE FULL BOARD OF DIRECTORS PRIOR TO THE EXTENDED DUE DATE OF THE RETURN. THE BOARD WILL BE INFORMED THAT THE EXECUTIVE COMMITTEE HAS REVIEWED AND APPROVED THE 990. IF ANY BOARD MEMBER HAS ANY QUESTIONS OR CONCERNS THEY WILL BE INSTRUCTED TO CONTACT THE SVP/CFO, WHO WILL RESOLVE THEIR INQUIRIES PROMPTLY. FORM 990, PART VI, SECTION B, LINE 12C ALL DIRECTORS, OFFICERS, AND KEY PERSONS WILL, AT LEAST ANNUALLY THEREAFTER, FILE A WRITTEN CONFLICT OF INTEREST DISCLOSURE STATEMENT WITH HEALTHIX' AVP OF COMPLIANCE, PRIVACY OFFICER. HEALTHIX' AVP OF COMPLIANCE, PRIVACY OFFICER WILL PROVIDE A SUMMARY OF ALL COMPLETED STATEMENTS TO THE CHAIR OF THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD FOR REVIEW. A NEW DIRECTOR MUST FILE CONFLICT OF INTEREST PRIOR TO BEING ELECTED TO BECOME A HEALTHIX BOARD MEMBER. FOR DIRECTORS, THE CONFLICT OF INTEREST DISCLOSURE STATEMENT WILL SPECIFICALLY INCLUDE, AMONG OTHER DISCLOSABLE CONFLICTS OF INTEREST, A STATEMENT IDENTIFYING, TO THE BEST OF THE DIRECTOR'S KNOWLEDGE, ANY ENTITY OF WHICH HE OR SHE IS AN OFFICER, DIRECTOR, TRUSTEE, MEMBER, OWNER (EITHER AS A SOLE PROPRIETOR OR A PARTNER), OR EMPLOYEE AND WITH WHICH HEALTHIX HAS A RELATIONSHIP, AND ANY TRANSACTION IN WHICH HEALTHIX IS A PARTICIPANT AND IN WHICH THE DIRECTOR MIGHT HAVE A DISCLOSABLE CONFLICT OF INTEREST. ALL COMPLETED CONFLICT OF INTEREST DISCLOSURE STATEMENTS THAT RAISE AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST, OR THAT CREATE THE APPEARANCE OF AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST, WILL BE FORWARDED BY THE CHAIR OF THE AUDIT AND COMPLIANCE COMMITTEE TO THE AUDIT AND COMPLIANCE COMMITTEE FOR THEIR CONSIDERATION. THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD WILL CONDUCT A FULL REVIEW OF ALL MATTERS (E.G., CONTRACTS, TRANSACTIONS OR ARRANGEMENTS) FOR WHICH AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST OR THE APPEARANCE OF AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST HAS BEEN IDENTIFIED. IN SO DOING, THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD WILL: A. CONSIDER ALL RELEVANT FACTS AND CIRCUMSTANCES INVOLVED IN THE MATTER, AND IN PARTICULAR, WHAT IS FAIR, REASONABLE AND IN THE BEST INTERESTS OF HEALTHIX; B. EXCLUDE THE AFFECTED INDIVIDUAL(S) FROM BEING PRESENT AT OR PARTICIPATING IN, OR BEING COUNTED IN THE QUORUM FOR, THE DELIBERATIONS OR VOTING ON THE MATTER; C. PROHIBIT THE AFFECTED INDIVIDUAL(S) FROM ANY ATTEMPT TO INFLUENCE IMPROPERLY THE DELIBERATIONS OR VOTING ON THE MATTER; D. PERMIT THE AFFECTED INDIVIDUAL(S), UPON REQUEST OF THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD, TO PRESENT INFORMATION CONCERNING THE MATTER AT A MEETING PRIOR TO COMMENCEMENT OF DELIBERATIONS OR VOTING ON THE MATTER. E. NOT PERMIT ANY DIRECTOR TO VOTE OR BE COUNTED IN DETERMINING THE QUORUM FOR ANY VOTE, ON ANY TRANSACTION BETWEEN HEALTHIX AND ANOTHER CORPORATION, FIRM, ASSOCIATION OR OTHER ENTITY IN WHICH THE DIRECTOR IS AN OFFICER OR DIRECTOR OR HAS A DIRECT OR INDIRECT SUBSTANTIAL FINANCIAL INTEREST. THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD WILL MAKE A FINAL AND BINDING DETERMINATION AS TO WHETHER A CONFLICT OF INTEREST EXISTS OR MAY EXIST ON ANY MATTER IN WHICH THERE IS A DISCLOSABLE CONFLICT OF INTEREST, AND WHAT COURSE HEALTHIX WILL TAKE IN CONNECTION WITH THE MATTER. THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD WILL CONTEMPORANEOUSLY DOCUMENT IN WRITING IN APPROPRIATE MINUTES OF ANY MEETING AT WHICH THE MATTER IS DELIBERATED OR VOTED UPON ALL DELIBERATIONS AND DETERMINATIONS RELATING THERETO, INCLUDING, AT A MINIMUM: 1. THE NAMES AND POSITIONS OF PERSONS WHO DISCLOSED THAT THEY WERE RELATED PARTIES OR OTHERWISE WERE FOUND TO BE RELATED PARTIES OR TO HAVE A CONFLICT OF INTEREST, A DESCRIPTION OF THE NATURE OF THE RELATIONSHIP AND/OR SUBSTANTIAL FINANCIAL INTEREST WHICH GAVE RISE TO SUCH DISCLOSURE OR IDENTIFICATION, AND A DESCRIPTION OF THE CONTRACT, TRANSACTION OR ARRANGEMENT AT ISSUE; 2. THE NAMES OF THE AUDIT AND COMPLIANCE COMMITTEE WHO WERE PRESENT DURING THE TAKING OF THE ACTION TO DETERMINE WHETHER A CONFLICT OF INTERESTS WAS PRESENT, AND THE BASIS FOR THERE BEING A QUORUM FOR THE TAKING OF SUCH ACTION WITHOUT INCLUDING ANY RELATED PARTIES OR AFFECTED PARTIES; 3. THE STEPS TAKEN BY THE AUDIT AND COMPLIANCE COMMITTEE MEMBERS OF THE BOARD TO DETERMINE WHETHER A CONFLICT OF INTEREST WAS PRESENT; 4. THE AUDIT AND COMPLIANCE COMMITTEE BOARD MEMBER'S DECISION AS TO WHETHER A CONFLICT OF INTERESTS WAS PRESENT AND THE BASIS FOR SUCH DECISION; 5. THE AUDIT AND COMPLIANCE COMMITTEE BOARD MEMBER'S DECISION AS TO WHETHER TO PROCEED WITH THE MATTERS (INCLUDING, BUT NOT NECESSARILY LIMITED TO, WHETHER THE MATTER IS AS FAIR AND REASONABLE TO HEALTHIX AS WOULD OTHERWISE THEN BE OBTAINABLE BY HEALTHIX) AND THE NAMES OF THE PERSONS WHO VOTED TO APPROVE THE MATTER. FORM 990, PART VI, SECTION B, LINE 15 IN 2019, THE COMPANY ENGAGED THE SERVICES OF AN INDEPENDENT COMPENSATION CONSULTING COMPANY, THE "JER HR GROUP, LLC,", WHICH PERFORMED A FORMAL MARKET STUDY AND PROVIDED RANGES FOR SALARIES FOR ITS CEO, EXECUTIVES, KEY EMPLOYEES AND FOR MOST POSITIONS IN THE COMPANY. THIS CONSULTANTS' REPORT WAS FINALIZED IN JANUARY 2020 & THE REPORT PROVIDED A VARIETY OF DATA, INCLUDING THE MEDIAN MARKET SALARY FOR MOST POSITIONS. THIS COMPENSATION SURVEY WAS REFERRED TO AGAIN IN 2022 AND 2023 AS A GENERAL GUIDE TO SET COMPENSATION RANGES. IN ADDITION, THE COMPANY CONSTANTLY MONITORS COMPENSATION LEVELS FOR THE MARKET IN WHICH IT OPERATES, TO ENSURE THAT ITS EMPLOYEES ARE COMPENSATED WITHIN MARKET PARAMETERS. ALSO, IN 2022, THE COMPANY ENGAGED THE SAME INDEPENDENT CONSULTING COMPANY TO SEE IF THE COMPENSATION OF EXECUTIVE MANAGEMENT WAS IN LINE WITH CURRENT MARKET CONDITIONS. NO ADJUSTMENTS TO EXECUTIVE SALARIES WERE NEEDED AS IT WAS DETERMINED THAT THEY WERE WITHIN THE PARAMETERS INDICATED. GOALS WERE SET FOR ALL EMPLOYEES AT THE BEGINNING OF 2023, AND THEIR PERFORMANCE WAS MEASURED AGAINST GOALS AFTER 2023 CONCLUDED. BONUSES WHICH WERE ACCRUED AT 12/31/22 (BASED ON 2022 PERFORMANCE) WERE PAID IN 2023, AND THOSE WHICH WERE ACCRUED AT 12/31/23 (BASED ON 2023 PERFORMANCE) WERE PAID OUT IN 2024. THE INCENTIVE COMPENSATION (I.E. BONUS) AND MERIT INCREASE PROGRAMS WERE APPROVED BY THE EXECUTIVE COMMITTEE FOR BOTH 2023 & 2022, AND WERE ALSO DISTRIBUTED TO ALL EMPLOYEES. THE EXECUTIVE COMMITTEE HAS SERVED AS HEALTHIX' COMPENSATION COMMITTEE. THE BY-LAWS CREATE A COMMITTEE OF THE BOARD WITH FULL POWERS OF THE BOARD TO REVIEW AND APPROVE THE COMPENSATION OF OFFICERS AND OTHER KEY EMPLOYEES. THE COMMITTEE, WHICH IS HEALTHIX'S EXECUTIVE COMMITTEE, CONSISTS OF TRUSTEES WHO HAVE NO CONNECTION TO HEALTHIX EXCEPT AS TRUSTEES AND THEY HAVE NO CONFLICTS AS TO MATTERS THEY CONSIDER. THE COMMITTEE MEETS SEVERAL TIMES A YEAR AS NEEDED, AND REVIEWS AND DETERMINES CEO COMPENSATION AS WELL AS THE OVERALL MERIT AND INCENTIVE COMPENSATION PROGRAMS FOR THE REST OF THE COMPANY. AS A RESULT OF THE INDEPENDENT SURVEYS INDICATED ABOVE, THE COMMITTEE HAS LET THE CEO DETERMINE COMPENSATION ADJUSTMENTS FOR OFFICERS AND KEY PERSONNEL, BASED ON THAT SURVEY'S RESULTS. THE EXECUTIVE COMMITTEE APPROVES INCENTIVE COMPENSATION FOR THE COMPANY'S SENIOR LEADERSHIP TEAM. THIS PROCESS WAS LAST UNDERTAKEN IN 2023. THE EXECUTIVE COMMITTEE'S APPROVAL FOR CEO COMPENSATION IS DOCUMENTED VIA THE COMMITTEE CHAIR'S SIGNATURE ON THE CEO'S PAYROLL CHANGE FORM. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS FORM 990 AND FORM 1023 AVAILABLE FOR PUBLIC INSPECTION AS REQUIRED UNDER SECTION 6104 OF THE INTERNAL REVENUE CODE. IT IS POSTED ON GUIDESTAR.ORG AND OTHER SIMILAR TYPES OF WEBSITES. IN ADDITION, THE FINANCIAL STATEMENTS, CONFLICT OF INTEREST POLICY, ARTICLES OF INCORPORATION AND BY-LAWS ARE ALSO AVAILABLE UPON WRITTEN REQUEST OR BY CALLING THE ORGANIZATION DIRECTLY. FORM 990, PART XII, LINE 2C: THE ORGANIZATION'S AUDIT AND COMPLIANCE COMMITTEE ASSUMES RESPONSIBILITY FOR THE OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF ITS INDEPENDENT AUDITORS. THE POLICY FOR SELECTION AND OVERSIGHT OF THE INDEPENDENT AUDITORS HAS NOT CHANGED SINCE LAST YEAR.